Oxford Biomedica
Oxford Biomedica is a biopharmaceutical company focused on gene and cell therapy, specializing in the development, manufacturing, and advancement of lentiviral vector-based medicines and related cell therapies. The company leverages its LentiVector platform to deliver therapeutic genes into non-dividing cells and collaborates with major pharmaceutical firms to progress both internal candidates and externally funded programs. Its internal pipeline targets diseases of the eye and the central nervous system, while ongoing partnerships span multiple therapeutic areas across Phase I/II and beyond. Oxford Biomedica also operates as a contract development and manufacturing organization, offering viral vector development and manufacturing services through OXB Solutions. Founded in 1995 and headquartered in Oxford, United Kingdom, the company maintains a global collaboration network with industry and academic partners.
Top Regions
Top Stages
2 past transactions
ABL Europe
Acquisition in 2023
ABL Europe is a company focused on bioproduction, quality control services, and gene therapy, dedicated to supporting the health industry. It develops and manufactures viral vectors to enhance the effectiveness of therapeutic interventions. By providing innovative solutions, ABL Europe aims to contribute to long-term public health outcomes for its clients. The company's expertise in these specialized areas positions it as a key player in advancing healthcare technologies.
Oxxon Therapeutics
Acquisition in 2007
Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer.
To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease.
The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV.
In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.